- Home
- SXC vs COLL Comparison
SXC vs COLL Comparison
Compare SXC & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXC
- COLL
- Stock Information
- Founded
- SXC 1960
- COLL 2002
- Country
- SXC United States
- COLL United States
- Employees
- SXC N/A
- COLL N/A
- Industry
- SXC Steel/Iron Ore
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- SXC Industrials
- COLL Health Care
- Exchange
- SXC Nasdaq
- COLL Nasdaq
- Market Cap
- SXC 802.2M
- COLL 910.2M
- IPO Year
- SXC N/A
- COLL 2015
- Fundamental
- Price
- SXC $9.24
- COLL $30.00
- Analyst Decision
- SXC Strong Buy
- COLL Strong Buy
- Analyst Count
- SXC 1
- COLL 5
- Target Price
- SXC $13.00
- COLL $43.60
- AVG Volume (30 Days)
- SXC 909.6K
- COLL 444.8K
- Earning Date
- SXC 04-30-2025
- COLL 05-08-2025
- Dividend Yield
- SXC 5.24%
- COLL N/A
- EPS Growth
- SXC 64.98
- COLL 43.56
- EPS
- SXC 1.12
- COLL 1.86
- Revenue
- SXC $1,935,400,000.00
- COLL $631,449,000.00
- Revenue This Year
- SXC N/A
- COLL $20.00
- Revenue Next Year
- SXC $3.70
- COLL $3.93
- P/E Ratio
- SXC $8.18
- COLL $16.09
- Revenue Growth
- SXC N/A
- COLL 11.41
- 52 Week Low
- SXC $7.47
- COLL $27.28
- 52 Week High
- SXC $12.82
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- SXC 48.27
- COLL 51.96
- Support Level
- SXC $8.92
- COLL $29.01
- Resistance Level
- SXC $9.30
- COLL $30.53
- Average True Range (ATR)
- SXC 0.24
- COLL 0.89
- MACD
- SXC 0.03
- COLL 0.04
- Stochastic Oscillator
- SXC 57.14
- COLL 62.91
About SXC SunCoke Energy Inc.
SunCoke Energy Inc operates as an independent producer of coke in the Americas. The company operates through three segments: Domestic Coke, Brazil Coke, and Logistics. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal producing, and other manufacturing-based customers.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.